BTIG Maintains Buy on Carlsmed, Raises Price Target to $26
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $24 to $26.
BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $24 to $26.